Endo International (NASDAQ:ENDP) (TSE:ENL) had its price objective lifted by investment analysts at BMO Capital Markets to $16.00 in a report released on Friday, The Fly reports. The brokerage presently has a “market perform” rating on the stock. BMO Capital Markets’ price target points to a potential upside of 2.24% from the company’s current price. The analysts noted that the move was a valuation call.

Other equities analysts have also issued research reports about the stock. Citigroup raised shares of Endo International from a “neutral” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Wednesday, June 27th. Cantor Fitzgerald set a $12.00 price target on shares of Endo International and gave the company a “hold” rating in a report on Wednesday. Leerink Swann boosted their price target on shares of Endo International from $12.00 to $18.00 and gave the company a “market perform” rating in a report on Thursday. Zacks Investment Research raised shares of Endo International from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 1st. Finally, ValuEngine raised shares of Endo International from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company’s stock. Endo International currently has a consensus rating of “Hold” and an average price target of $11.64.

Shares of Endo International opened at $15.65 on Friday, Marketbeat Ratings reports. Endo International has a 1 year low of $5.27 and a 1 year high of $17.34. The firm has a market cap of $3.54 billion, a P/E ratio of 5.09, a P/E/G ratio of 6.29 and a beta of 0.49. The company has a debt-to-equity ratio of -132.64, a quick ratio of 0.88 and a current ratio of 1.07.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.22. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The business had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. During the same quarter in the previous year, the firm posted $0.93 earnings per share. Endo International’s revenue was down 18.4% compared to the same quarter last year. analysts predict that Endo International will post 2.6 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in shares of Endo International by 27.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 104,155 shares of the company’s stock worth $994,000 after purchasing an additional 22,644 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Endo International by 115.7% in the 2nd quarter. Arizona State Retirement System now owns 293,200 shares of the company’s stock worth $2,765,000 after purchasing an additional 157,252 shares during the last quarter. Diamond Hill Capital Management Inc. grew its holdings in shares of Endo International by 1.0% in the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after purchasing an additional 10,600 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Endo International by 13.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock worth $23,074,000 after purchasing an additional 284,599 shares during the last quarter. Finally, River & Mercantile Asset Management LLP grew its holdings in shares of Endo International by 18.6% in the 2nd quarter. River & Mercantile Asset Management LLP now owns 554,835 shares of the company’s stock worth $5,229,000 after purchasing an additional 87,102 shares during the last quarter. 96.27% of the stock is currently owned by hedge funds and other institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: Leveraged Buyout (LBO)

The Fly

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.